Jiří Lísal graduated in biophysics at the Charles University in Prague and gained PhD degree in biochemistry at the University of Helsinki in Finland. From 2002 to 2006 he worked at the Institute of Biotechnology in Helsinki and then he received Human Frontiers Science Program Long-term Fellowship allowing him to spend a two-year postdoc at the Stanford University School of Medicine in California. Jiří produced several high-impacted scientific publications during those years.
In 2009 Jiří decided to move to pharmaceutical industry. He started a new career at Zentiva which belonged to the pharmaceutical giant Sanofi at that time. At Zentiva he held the position of Global Project Manager and also shortly led the pharmaceutical development department in Hlohovec Slovakia during the challenging times of its divestment. In 2014 he was appointed to the role of Research and Development Director at PRO.MED.CS, the second biggest pharmaceutical company in Czech Republic. Jiří likes the challenges of streamlining and improving of company processes that help to bring the new therapies to the patients as soon as possible. Jiří joined SOTIO in 2019 as Chief Operating Officer.